A 2014 correlative structural and functional study profiled twelve representative environmental pollutants against the human estrogen receptors ERα and ERβ and found that these chemically diverse ligands act as full agonists, graded partial agonists, or antagonists by engaging different combinations of the N-terminal activation function AF-1 and the C-terminal activation function AF-2, with activities that depend on receptor subtype and cell type. The study identified as its central unresolved question the structural basis of this interdomain communication — unknown because no three-dimensional structure of an entire nuclear receptor was available — that is, how ligand-binding events in the ligand-binding domain are transduced to modulate AF-1 activity and coregulator recruitment. This core remains open: no full-length ERα or ERβ structure exists at interpretable (sidechain) resolution, and the molecular mechanism by which ligand-specific ligand-binding-domain states modulate AF-1 remains undetermined, as does its cell-type dependence through coregulator complements.

Background

Endocrine-disrupting chemicals (EDCs) are exogenous environmental contaminants — plasticizers, fungicides, mycotoxins, industrial intermediates and their derivatives — that interfere with hormonal signaling, and a principal route of their action is direct binding to nuclear receptors (NRs), a family of ligand-regulated transcription factors. The estrogen receptors ERα and ERβ (NR3A1/NR3A2) are prime EDC targets: like all NRs they are modular proteins with a variable N-terminal domain (NTD) containing the ligand-independent activation function AF-1, a conserved DNA-binding domain (DBD) that recognizes estrogen response elements, a hinge region, and a C-terminal ligand-binding domain (LBD) whose ligand-dependent activation function AF-2 is formed largely by the position of the amphipathic helix H12 over the hydrophobic ligand-binding pocket. Ligands that stabilize different LBD conformations — the endogenous hormone 17β-estradiol, synthetic drugs, or chemically diverse environmental compounds — produce graded transcriptional outputs ranging from full agonism to partial agonism to antagonism, much like the selective estrogen receptor modulators used clinically, whose tissue-selective actions arise because transcriptional output depends on which coactivators (e.g., the p160/SRC-family coactivator SRC-3 and the histone acetyltransferase p300) the liganded receptor recruits, and the coregulator complement differs between cell types. In this context, Delfosse and colleagues (2014) combined crystal structures of twelve environmental ligands bound to ER LBDs with binding-affinity, transactivation, and coregulator-recruitment measurements and made a key observation: environmental ligands of comparable affinity can activate ERα and ERβ differently because they use different combinations of AF-1 and AF-2, with the balance varying by receptor subtype and cell line — yet the molecular pathway connecting the ligand-bound LBD to AF-1 could not be explained, because no three-dimensional structure of an entire (full-length) nuclear receptor existed; decades of NR structural biology had produced only isolated LBD and DBD structures plus a handful of multidomain crystal and integrative models that omit the intrinsically disordered NTD that carries AF-1. Subsequent work has filled in parts of the surrounding landscape — a low-resolution cryo-EM quaternary model located AF-1 within the DNA-bound ERα:SRC-3:p300 assembly, an integrative small-angle X-ray scattering and footprinting model revealed DBD–LBD (not AF-1–LBD) cross-talk in ERα, cryo-EM structures of the full-length androgen receptor bound to DNA and coactivators were determined at 13–20 Å resolution, and no sidechain-resolved structure of any full-length NR, and no full-length ER structure at interpretable (sidechain) resolution, has been obtained (Choi et al. 2023). Functional and computational studies have meanwhile linked sub-angstrom ligand-specific LBD perturbations to cellular activity profiles and built validated screening models for EDC bioactivity from high-throughput assays and LBD docking — but none of these reaches the AF-1 side of the communication path. The unresolved target is therefore the interdomain allosteric mechanism itself: the structural and mechanistic basis by which ligand-specific LBD (AF-2) states are transmitted to the disordered N-terminal AF-1, and how this produces subtype-, ligand-, and cell-type-selective transcriptional outputs and coregulator recruitment for environmental ligands.

Problem Statement

Determine the structural and mechanistic basis of interdomain communication between the N-terminal activation function AF-1 and the C-terminal activation function AF-2 in the human estrogen receptors ERα and ERβ: how ligand-specific conformations of the ligand-binding domain — as induced by 17β-estradiol and by chemically diverse environmental ligands acting as full agonists, graded partial agonists, or antagonists — are transduced to modulate AF-1-mediated transcriptional activation and the recruitment of coactivators such as SRC-family proteins and p300. A resolution requires identifying the contacts, interaction surfaces, or conformational ensembles that constitute the NTD(AF-1)–LBD(AF-2) communication path — in a full-length estrogen receptor or at the interface itself — and showing how the proposed mechanism accounts for the observed ligand-graded and subtype-dependent activities of environmental ligands. A resolution must also be concordant with the environmental chemicals profiled in the source study and with the cell-type dependence arising from differential coregulator recruitment; these are required constraints on the proposed mechanism rather than separate deliverables.

References

  1. Delfosse V, Grimaldi M, Cavaillès V, Balaguer P, Bourguet W (2014). Structural and Functional Profiling of Environmental Ligands for Estrogen Receptors. Environmental Health Perspectives 122(12):1306–1313. doi:10.1289/ehp.1408453, https://doi.org/10.1289/ehp.1408453
  2. Yi P, Wang Z, Feng Q, Pintilie GD, Foulds CE, Lanz RB, Ludtke SJ, Schmid MF, Chiu W, O'Malley BW (2015). Structure of a biologically active estrogen receptor-coactivator complex on DNA. Molecular Cell 57(6):1047–1058. doi:10.1016/j.molcel.2015.01.025, https://doi.org/10.1016/j.molcel.2015.01.025
  3. Yu X, Yi P, Hamilton RA, Shen H, Chen M, Foulds CE, Mancini MA, Ludtke SJ, Wang Z, O'Malley BW (2020). Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes. Molecular Cell 79(5):812–823.e4. doi:10.1016/j.molcel.2020.06.031, https://doi.org/10.1016/j.molcel.2020.06.031
  4. Choi WJ, Haratipour Z, Blind RD (2023). Full-length nuclear receptor allosteric regulation. Journal of Lipid Research 64(8):100406. doi:10.1016/j.jlr.2023.100406, https://doi.org/10.1016/j.jlr.2023.100406
  5. Huang W, Peng Y, Kiselar J, Zhao X, Albaqami A, Mendez D, Chen Y, Chakravarthy S, Gupta S, Ralston C, Kao HY, Chance MR, Yang S (2018). Multidomain architecture of estrogen receptor reveals interfacial cross-talk between its DNA-binding and ligand-binding domains. Nature Communications 9:3520. doi:10.1038/s41467-018-06034-2, https://doi.org/10.1038/s41467-018-06034-2
  6. Liu X, Matsuyama Y, Sugiyama M, Suyama K, Nose T, Shimohigashi M, Shimohigashi Y (2024). The N-terminal activation function AF-1 domain of ERα interacts directly with the C-terminal AF-2-holding ligand-binding domain to recruit the coactivator proteins. PLoS ONE 19(10):e0312276. doi:10.1371/journal.pone.0312276, https://doi.org/10.1371/journal.pone.0312276
  7. Nwachukwu JC, Srinivasan S, Bruno NE, Nowak J, Wright NJ, Minutolo F, Rangarajan ES, Izard T, Yao XQ, Grant BJ, Kojetin DJ, Elemento O, Katzenellenbogen JA, Nettles KW (2017). Systems Structural Biology Analysis of Ligand Effects on ERα Predicts Cellular Response to Environmental Estrogens and Anti-hormone Therapies. Cell Chemical Biology 24(1):35–45. doi:10.1016/j.chembiol.2016.11.014, https://doi.org/10.1016/j.chembiol.2016.11.014
  8. Iwamoto M, Masuya T, Hosose M, Tagawa K, Ishibashi T, Suyama K, Nose T, Yoshihara E, Downes M, Evans RM, Matsushima A (2021). Bisphenol A derivatives act as novel coactivator-binding inhibitors for estrogen receptor β. Journal of Biological Chemistry 297(5):101173. doi:10.1016/j.jbc.2021.101173, https://doi.org/10.1016/j.jbc.2021.101173
  9. Grimaldi M, Boulahtouf A, Toporova L, Balaguer P (2019). Functional profiling of bisphenols for nuclear receptors. Toxicology 420:39–45. doi:10.1016/j.tox.2019.04.003, https://doi.org/10.1016/j.tox.2019.04.003
  10. Browne P, Judson RS, Casey WM, Kleinstreuer NC, Thomas RS (2015). Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model. Environmental Science & Technology 49(14):8804–8814. doi:10.1021/acs.est.5b02641, https://doi.org/10.1021/acs.est.5b02641
  11. Tan H, Wang X, Hong H, Benfenati E, Giesy JP, Gini GC, Kusko R, Zhang X, Yu H, Shi W (2020). Structures of Endocrine-Disrupting Chemicals Determine Binding to and Activation of the Estrogen Receptor α and Androgen Receptor. Environmental Science & Technology 54(18):11424–11433. doi:10.1021/acs.est.0c02639, https://doi.org/10.1021/acs.est.0c02639
  12. Tan H, Chen Q, Hong H, Benfenati E, Gini GC, Zhang X, Yu H, Shi W (2021). Structures of Endocrine-Disrupting Chemicals Correlate with the Activation of 12 Classic Nuclear Receptors. Environmental Science & Technology 55(24):16552–16562. doi:10.1021/acs.est.1c04997, https://doi.org/10.1021/acs.est.1c04997
  13. Zhao L, Xue Q, Zhang H, Hao Y, Yi H, Liu X, Pan W, Fu J, Zhang A (2024). CatNet: Sequence-based deep learning with cross-attention mechanism for identifying endocrine-disrupting chemicals. Journal of Hazardous Materials 465:133055. doi:10.1016/j.jhazmat.2023.133055, https://doi.org/10.1016/j.jhazmat.2023.133055
  14. Jin J, Huang F, Chen Q, Yu H, Tan H, Shi W (2025). Dimerization-Driven Quantitative Modeling of Endocrine Disruption via Sex Hormone Receptors: Divergent Predictions for Estrogen Receptor α and Androgen Receptor. Environmental Science & Technology Letters 13:49–56. doi:10.1021/acs.estlett.5c01043, https://doi.org/10.1021/acs.estlett.5c01043
  15. Rancière F, Lyons JG, Loh VHY, Botton J, Galloway T, Wang T, Shaw JE, Magliano DJ (2015). Bisphenol A and the risk of cardiometabolic disorders: a systematic review with meta-analysis of the epidemiological evidence. Environmental Health 14(1):46. doi:10.1186/s12940-015-0036-5, https://doi.org/10.1186/s12940-015-0036-5
  16. Balaguer P, Delfosse V, Grimaldi M, Bourguet W (2017). Structural and functional evidences for the interactions between nuclear hormone receptors and endocrine disruptors at low doses. Comptes Rendus Biologies 340(9–10):414–420. doi:10.1016/j.crvi.2017.08.002, https://doi.org/10.1016/j.crvi.2017.08.002